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Abstract
Background: Currently, there are not many studies of correlations between myelofibrosis (MF) and clinical-laboratory data 
on multiple myeloma (MM).
Methods and Results: In our study, MF was evaluated according to the scale of the European consensus (2005). Additionally, 
we used an automated morphometric study. The inverse correlations between the prevalence of MF and the total number of 
erythroid cells and megakaryocytes, as well as hemoglobin level were found. The total relative area of fibrosis tissue (Srel.fibr.tis.) 
in initial and advanced MF>20% was associated with anemia requiring a blood transfusion.The development of severe anemia 
was observed in patients with a greater relative area of      Srel.fibr.tis. The direct correlations between Srel.fibr.tis. and relative area 
of tumor tissue (Srel.tum.tis.), between Srel.fibr.tis. and the level of total serum protein, between Srel.fibr.tis. and daily proteinuria 
were found both in initial and in advanced MF. Additionally, a direct correlation between Srel.fibr.tis. and the number of plasma 
cells was revealed in initial MF. Greater Srel.fibr.tis. in initial and advanced MF was found in patients with chronic renal failure. 
Conclusion: The clinical-laboratory significance of MF in MM is an inhibition of erythroid cells and megakaryocytes and 
development of anemia. The relative area of     fibrous tissue is a marker of tumor volume and tumor progression.
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Introduction
Currently, the role of MF in patients with MM is explored 
actively. Advanced MF directly correlates with the number 
of poorly differentiated plasma cells, which by themselves 
are  poor  prognostic  markers.  The  literature  suggests  that 
simultaneous  morphological  study  of  tumor  cells  and  MF 
during  monitoring  of  MM  can  provide  better  prognostic 
significance than an isolated study of tumor substrate [1].
Patients with increased fibrosis of the bone marrow also 
had a median survival time of just 11 months [2-4]. Patients 
with resistant or progressive disease had permanent elevated 
levels  of  serum  procollagen  III  aminoterminal  propeptide, 
which is considered as the marker of fibrogenesis. In most 
patients  with  responsive  disease,  serum  procollagen  III 
aminoterminal  propeptide  is  normalized,  and  no  relapses 
were observed in patients who had normal levels of serum 
procollagen III aminoterminal propeptide [5].  
Despite the attention to the prognostic significance of MF 
in patients with MM, there aren’t many studies of correlations 
between MF and blood-forming tissue and between MF and 
disease severity, or of associations between MF and anemia.
Therefore, the purpose of our work was to evaluate the 
associations between different clinical and laboratory signs of 
MM, to determine the indicators of MF, which are considered 
as the markers of clinically significant changes.
Material and Methods
We examined 42 patients with MM who were treated 
in Novosibirsk State Regional Hospital from 2006 to 2012. 
Informed consent was obtained from each patient. Patients 
were divided into three groups: Group 1 - initial presentation 
of  the  disease  (before  chemotherapy),  Group  2  -  response 
to  chemotherapy  (response  to  treatment  is  not  less  than 
the minimum), Group 3 – relapse (before the next line of 
chemotherapy). We regarded initial presentation of the disease 
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and relapse of MM as the active phase of the disease. Patient 
characteristics are shown in Table 1. Nine people among Group 
2 patients received the 1st line therapy, and five people from 
this group received the 2nd line therapy. Five people among 
Group 3 patients received the 1st line therapy, and two people 
from this group received the 2nd line therapy. The treatment 
was carried out under schemes containing at least two of the 
following drugs: melphalan, prednisone, cyclophosphamide, 
bortezomib, dexamethasone.
We  used  standard  criteria  [6],  Russian  clinical 
practice  guidelines  for  the  diagnosis  and  treatment  of 
lymphoproliferative diseases[7], as well as the Durie-Salmon 
criteria[8],  ISS  [9],  the  criteria  of  the  European  Group  of 
Blood and Transplant Bone Marrow - EBMT [10] to verify the 
diagnosis, staging, and treatment evaluation of MM. Chronic 
renal failure (CRF) was diagnosed according to the  Durie-
Salmon criteria [8]. 
Methods for MF evaluation 
MF degree was evaluated according to the scale of the 
European consensus [11]. MF of the 1st degree (MF-1) was 
regarded as an initial fibrosis; MF of the 2nd and the 3rd degree 
as an advanced fibrosis [12].
An  automated  morphometric  study  of  MF  was 
performed using an image analysis software (AxioVision 4.6), 
camera (Axio Cam),  and microscope (Zeiss). The absolute 
area  of  fibrous  tissue  was  measured  in  paraffin-embedded 
trephine bone marrow biopsies, impregnated with silver by the 
method of Gomory and stained by the method of van Gieson 
with magnification 200. The thickness of paraffin-embedded 
trephine bone marrow biopsies was 4μm. The absolute area 
of hematopoietic tissue and the absolute area of tumor tissue 
were measured in slices of marrow stained with H&E. We 
studied all the bone marrow cavities of one slice of marrow, 
which corresponds to 5–7 fields of view of the microscope and 
20–30 camera view fields (depending on the size of the slice 
marrow). The area of one field of view was 364000 μm2 (0.7 
mm2). The area of fibrous tissue was evaluated with respect to 
hematopoietic tissue. The absolute total area of fibrous tissue 
(Sfibr.tis.) within the same slice was obtained by adding the 
area of fibrous tissue in all fields- of-view of the camera. The 
absolute total area of hematopoietic tissue (Shematopoet. tis.) 
was calculated in an analogical way, then the relative area of 
fibrous tissue was calculated (Srel.fibr.tis.) by the formula Srel.
fibr.tis.= Sfibr.tis. / Shematopoet.tis. · 100%. The area of tumor 
tissue  was  evaluated  relative  to  the  normal  hematopoietic, 
bone, and adipose tissues. The relative area of     tumor tissue 
(S rel.tum.tis.) was calculated by the formula Srel.tum.tis. = 
Stum.tis. / (N · 364 000) · 100%, where Stum.tis. is absolute 
total area of tumor tissue, n – the number of analyzed fields of 
view, 364000 – the area of     one field of view.
Data of hemograms and myelograms were used for the 
study of quantitative indicators. The definition of indicators 
was performed on hematology analyzer Sysmex XT-2000i. 
Hemogram  included  a  number  of  erythrocytes,  platelets, 
granulocytes and lymphocytes, the level of hemoglobin and 
hematocrit.  Myelogram  included  the  number  of  erythroid, 
megakaryocytic,  granulocytic,  lymphoid  cells  and  plasma 
cells,  cells  of  bone  marrow  microenvironment:  reticular 
cells,  osteoblasts,  fibroblasts,  adipocytes,  adventitial  cells, 
endothelial cells, macrofages. Smears of bone marrow were 
stained with Romanovsky-Giemsa.
Statistical analysis was performed using the software 
package SPSS  (version 17.0). The mean (M) and standard 
deviation (SD were deduced. (Standard Deviation –SD). The 
Mann-Whitney (U Test) was used to compare the differences 
between the two independent groups (for nonparametric data). 
Pearson’s Correlation Coefficient (r) was used to determine 
the strength of the relationship between the two continuous 
variables.  Spearman’s  rank  correlation  coefficient  was 
also used. A value of P<0.05 and odds ratio (OR)>1.0 were 
considered statistically significant.
Results and discussion
There was an inverse correlation between Srel.fibr.tis. 
in initial MF and the total number of erythroid cells (r=-0.037, 
P=0.813), between Srel.fibr.tis. in advanced MF and the total 
number of erythroid cells (r=-0.496, P=0.031) in the active 
phase of MM. Additionally, a negative correlation between 
total Srel.fibr.tis. of initial and advanced MF and the number 
of megakarycytes was found in the active phase of MM (r=-
0.411, P=0.046). 
There was a negative correlation between Srel.fibr.tis. in 
advanced MF and hemoglobin levels (r=-0.420, p=0.047) in 
anemic patients in initial presentation of MM. Additionally, a 
negative correlation between Srel.fibr.tis. in advanced MF and 
the number of erythrocytes in peripheral blood, between Srel.
fibr.tis. in advanced MF and hematocrit (r=-0.560, P=0.030) 
was found.
Univariate  analysis  showed  that  total  Srel.fibr.tis.  in 
initial and advanced MF>20% was associated with anemia 
requiring a blood transfusion (hemoglobin <75 g/l, P=0.049, 
OR=1.62; CI=0.50-7.15).
The greatest Srel.fibr.tis. in initial (22.50±31.82%) and 
advanced  (25.0±2.83%)  MF  are  observed  in  patients  with 
severe anemia (P<0.001). 
Study  of  the  interrelationship  of  bone  marrow 
microenvironment  cells  (BMMC)  and  hematopoietic  cells 
in the bone marrow smears revealed an inverse correlation 
between the total number of erythroid cells and the number of 
Table 1.
 Clinical characteristics of patients with MM
Variable Group 1
(n=21)
Group 2
(n=14)
Group 3
(n=7)
Male 8/38.1% 6/42.9% 2/28.6%
Female 13/61.9% 8/57.1% 5/71.4%
Mean Age:
Men 66.75±3.18 60.33±4.72 65.0±6.0
Women 58.08±3.43 53.25±2.23 63.20±2.75
MM Stage by the Durie-Salmon Staging System:
I  7 2 1
II  6 7 3
III  8 5 374                                             T. Yu. Dolgikh et al / International Journal of BioMedicine 4(2) (2014) 72-75
macrophages in the relapse of MM (r=-0.999, P=0.025).
A  direct  correlation  between  the  number  of 
megakaryocytes and macrophages was revealed both in active 
phase (r=0.643, P=0.033), and in the phase of the response 
to  treatment  (r=0.864,  P=0.012).  Interactions  between  the 
BMMC and the lymphoid and granulocytic germ cells were 
not identified. 
We  did  not  find  correlations  between  the  number  of 
fibroblasts  and  the  number  of  the  erythroid,  granulocytic, 
lymphoid and megakaryocytic germ cells, nor did we find a 
relationship between the BMMC and peripheral blood cells, 
between the BMMC and hemoglobin level.
The correlations and associations of the prevalence of 
initial and advanced MF with such markers of tumor mass and 
tumor progression as Srel.tum.tis. and the number of plasma 
cells in the myelogram were analyzed.
The relative area of fibrous tissue in initial MF and Srel.
fibr.tis.  in  advanced  MF  directly  correlates  with  Srel.tum.
tis. (r=0.390, P=0.040 in initial MF and r = 0.390, P=0.040 
in  advanced  MF).  Results  of  multivariate  analysis  showed 
that initial MF was associated with the presence of tumor 
lesions  of  the  bone  marrow  (P=0.036,  OR=1.10;  CI=1.91-
45.58). A direct correlation between Srel.fibr.tis. in initial MF 
and the number of plasma cells in myelogram was revealed 
(r=0.577,P=0.005).
The  relative  area  of  fibrous  tissue  in  initial  MF 
(17.25±23.71%)  and  the  total  Srel.fibr.tis  in  initial  and 
advanced MF (24.44±25.37%) in the presence of CRF were 
significantly higher (P<0.05) than analogical indicators in the 
absence of CRF(2.60±6.30% and 6.18±9.68% respectively). 
A direct correlation between the level of total serum 
protein and Srel.fibr.tis. in initial MF was established (r=0.374, 
P=0.032). Additionally, a direct correlation between the level 
of daily proteinuria and Srel.fibr.tis. in initial MF was found 
(r=0.330, P=0.046).
We found a negative correlation between Srel.fibr.tis. 
and the total number of erythroid cells in the active phase of 
MM, probably due to intensive production of growth factors 
and cytokines in the process of tumor growth, causing the 
overproduction fibers of stromal microenvironment.
There was demonstrated in a murine model, that the 
active  phase  of  MM  is  associated  with  a  higher  number 
of  tumor-associated  fibroblasts  than  is  the  inactive  phase 
(response  to  chemotherapy).  Tumor-associated  fibroblasts 
produce  excessive  amounts  transforming  growth  factor-β, 
interleukin-6,  insulin-like  growth  factor-1,  vascular 
endothelial  growth  factor  and  fibroblast  growth  factor-2. 
Activated tumor-associated fibroblasts enhance chemotaxis, 
adhesion,  proliferation, and  resistance to  apoptosis  in  MM 
cells, contributing to disease progression. In turn, MM cells 
enhance the proliferation of tumor-associated fibroblasts [13].
Because  bone  marrow  fibroblast  is  a  key  cellular 
mediator of MF, producing factors that increase the growth of 
fibers of stromal microenvironment [14], as well as cytokines, 
which suppress erythropoiesis [15], it becomes obvious that 
there is an inverse correlation between Srel.fibr.tis. and the 
total number of erythroid cells.
Similar mechanisms, relating to erythroid cells, lie at the 
basis of the correlation between Srel.fibr.tis. and the number 
of  megakaryocytes.  Cytokine  inhibition  of  erythropoietin 
production also impaired the megakaryocytopoiesis [15].
More  likely,  the  association  of  total  Srel.fibr.tis.  in 
initial  and  advanced  MF  >  20%  with  hemoglobin  <  75g/l 
is a consequence of displacement of hematopoietic cells, as 
described in the primary MF [14].
Mechanical  displacement  of  hematopoietic  cells  is 
carried out as fibrotic fibers and tumor tissue [17]. Moreover, 
these two factors are interdependent, as shown in our study. 
So, Srel.fibr.tis. both in initial MF and in advanced MF directly 
correlates with Srel.tum.tis, Srel.fibr.tis. in initial MF directly 
correlates with the number of plasma cells.
The development of severe anemia is marked in patients 
with  greater  Srel.fibr.tis.  Pathogenetic  mechanisms  of  this 
phenomenon are the same ones associated with an imbalance 
of cytokines and mechanical displacement of hematopoietic 
cells,  which  underlies  the  formation  of  anemia  in  chronic 
disease [18].
The  data  of  myelogram  showed  no  relationships 
between  the  number  of  fibroblasts  and  total  number  of 
erythroid  cells.  Furthermore,  no  correlations  between  the 
number of fibroblasts in bone marrow smears and peripheral 
blood cell counts were found. This fact is probably due to the 
transformation of fibroblasts into myofibroblasts and matrix-
producing cells in the MF development [19]. 
Observed  correlations  between  the  number  of 
macrophages  and  the  total  number  of  erythroid  cells  have 
not been described in clinical studies. These results testify to 
the complexity of the relationships between different BMMC 
groups and require further study.
A direct correlation between Srel.fibr.tis. and the level of 
total serum protein, between Srel.fibr.tis. and daily proteinuria 
indicates the relationship between the tumor mass and MF, as 
total serum protein and daily proteinuria are markers of tumor 
volume. Greater Srel.fibr.tis. in initial and advanced MF in 
CRF patients compared with patients without CRF reflects the 
relationship of tumor growth and prevalence of MF, because 
CRF is a marker of tumor progression [20].
Conclusion
Thus for the first time, in this paper we show an inverse 
correlation between the prevalence of MF and the number of 
erythroid cells and megakaryocytes, between the prevalence 
of MF and hemoglobin level. We found that total Srel.fibr.tis. 
in initial and advanced MF>20% is associated with anemia 
requiring  a  blood  transfusion.  The  development  of  severe 
anemia was marked in patients with greater Srel.fibr.tis.
The results of the study suggest that the clinical and 
laboratory  significance  of  MF  in  patients  with  MM  is  the 
suppression  of  the  erythroid  and  megakaryocytic  germs, 
progression of anemia.
Direct  correlations  between  Srel.fibr.tis.  and  Srel.
tum.tis., Srel.fibr.tis. and the number of plasma cells in the 
myelogram, Srel.fibr.tis. and the level of total serum protein, 
between  Srel.fibr.tis.  and  daily  proteinuria,  as  well  as  the 
high Srel.fibr.tis. in initial and advanced MF in CRF patients, 75 T. Yu. Dolgikh / International Journal of BioMedicine 4(2) (2014) 72-75
compared with patients without CRF, permit consideration of 
Srel.fibr.tis. as a marker of tumor volume and progression.
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